IL17A and Splenomegaly: We hypothesize that after Apt-GA+Cur@μmS reaches the skin target expressing IL-17RA, upon irradiation with blue light, the synergistic effect of blue light therapy and topical administration of Apt-GA+Cur@μmS would alleviate splenic NO-mediated splenomegaly as well as reduce IL-17A expression in the skin.